Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P323 Successful validation of the quantum blue quantitative rapid test to monitor C-reactive protein in capillary blood of patients suffering from chronic inflammatory diseases

ECCO'20 Vienna

Year: 2020
Authors:

M. Takacs1, A. Hellige2, T. Schuster1, S. Schleifenbaum2, D. Föll2, J.M. Weber1

1BÜHLMANN Laboratories AG, Development, Schönenbuch, Switzerland, 2University Clinic Münster, Pediatric Rheumatology and Immunology, Münster, Germany

P324 Deep enteroscopy after balloon dilatation for differential diagnosis of small bowel stricture

ECCO'20 Vienna

Year: 2020
Authors:

C.H. Lim, J. Kim

Internal Medicine, The Catholic University of Korea, Seoul, Korea Republic of

P325 A propensity score-weighted comparison of vedolizumab and adalimumab in Crohn’s disease: Real-life data from the Sicilian Network for inflammatory bowel disease (SN-IBD)

ECCO'20 Vienna

Year: 2020
Authors:

F.S. Macaluso1, M. Ventimiglia1, W. Fries2, A. Viola2, A. Sitibondo2, M. Cappello3, B. Scrivo3, A. Busacca3, A.C. Privitera4, S. Camilleri5, S. Garufi5, R. Di Mitri6, F. Mocciaro6, N. Belluardo7, E. Giangreco7, C. Bertolami8, S. Renna1, R. Orlando1, G. Rizzuto1, M. Cottone1, A. Orlando1, Sicilian Network for Inflammatory Bowel Disease (SN-IBD)

1A.O.O.R. ‘Villa Sofia-Cervello’, IBD Unit - Department of Medicine, Palermo, Italy, 2A.O.U. Policlinico ‘G. Martino’, Inflammatory bowel disease Unit, Messina, Italy, 3A.O.U. Policlinico ‘G. Giaccone’, Gastroenterology and Hepatology Unit, Palermo, Italy, 4A.O. ‘Cannizzaro’, Inflammatory Bowel Disease Unit, Catania, Italy, 5A.O.O.R. ‘S. Elia- M. Raimondi’, Gastroenterology Unit, Caltanissetta, Italy, 6A.R.N.A.S. ‘Civico Di Cristina Benfratelli’, Gastroenterology and endoscopy Unit, Palermo, Italy, 7A.O. ‘Guzzardi’, Gastroenterology Unit, Vittoria, Italy, 8A.O.O.R. ‘Papardo Piemonte’, Gastroenterology Unit, Messina, Italy

P326 Reasons for and effectiveness of switching back to originator infliximab after a prior switch to CT-P13 biosimilar

ECCO'20 Vienna

Year: 2020
Authors:

S. Mahmmod1, J.P.D. Schultheiss1, A.C.I.T.L. Tan2, M.W.M.D. Lutgens3, L.P.L. Gilissen4, N. Mahmmod5, A.E. van der Meulen - de Jong6, G. Dijkstra7, A.A. van Bodegraven8, B. Oldenburg1, H.H. Fidder1

1Department of Gastroenterology and Hepatology, UMC Utrecht, Utrecht, The Netherlands, 2Department of Gastroenterology and Hepatology, Canisius Wilhelmina Ziekenhuis, Nijmegen, The Netherlands, 3Department of Gastroenterology and Hepatology, Elisabeth-TweeSteden Ziekenhuis, Tilburg, The Netherlands, 4Department of Gastroenterology and Hepatology, Catharina Ziekenhuis, Eindhoven, The Netherlands, 5Department of Gastroenterology and Hepatology, St. Antonius Ziekenhuis, Nieuwegein, The Netherlands, 6Department of Gastroenterology and Hepatology, Leiden UMC, Leiden, The Netherlands, 7Department of Gastroenterology and Hepatology, UMC Groningen, Groningen, The Netherlands, 8Department of Gastroenterology and Hepatology, Zuyderland Ziekenhuis, Sittard, The Netherlands

P327 Effectiveness of anti-TNF vs. vedolizumab as a second biologic in IBD: results from national Swedish registers

ECCO'20 Vienna

Year: 2020
Authors:

S. Rundquist1, M. Sachs2, C. Eriksson1, O. Olén3, S. Montgomery4, J. Halfvarson1, SWIBREG Study Group

1Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden, 2Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, 3Clinical Epidemiology Division, Department of Medicine Solna, Department of Clinical Science and Education Södersjukhuset, Karolinska Institutet, Stockholm, Sweden, 4Department of Clinical Epidemiology and Biostatistics, School of Medical Sciences, Örebro University, Örebro, Sweden

P328 Faecal microbiota transplantation as treatment for recurrent Clostridiodes difficile infection in patients with inflammatory bowel disease: Experiences of the Netherlands donor faeces bank

ECCO'20 Vienna

Year: 2020
Authors:

E. Van Lingen1, A.E. van der Meulen-de Jong1, K.E.W. Vendrik2, E.J. Kuijper2, E.M. Terveer2, J.J. Keller3

1Department of Gastroenterology and Hepatology, LUMC, Leiden, The Netherlands, 2Department of Medical Microbiology, LUMC, Leiden, The Netherlands, 3Department of Gastroenterology, Haaglanden Medical Center, The Hague, The Netherlands

P329 ECCO grant recipient: preliminary results of the HOT-TOPIC trial (Hyperbaric Oxygen Therapy for the Treatment Of Perianal fistulas In Crohn’s disease)

ECCO'20 Vienna

Year: 2020
Authors:

C. Lansdorp1, K. Gecse2, C. Buskens3, M. Löwenberg2, J. Stoker4, W. Bemelman3, G. D’Haens2, R. van Hulst1

1Department of Anaesthesiology/Hyperbaric Medicine, Academic Medical Centre, Amsterdam, The Netherlands, 2Department of Gastroenterology and Hepatology, Academic Medical Centre,Amsterdam, The Netherlands, 3Department of Surgery, Academic Medical Centre, Amsterdam, The Netherlands, 4Department of Radiology and Nuclear Medicine, Academic Medical Centre, Amsterdam, The Netherlands

P330 Inflammatory Bowel Disease (IBD) patients frequently report adverse drug reactions during biologic therapy: A multicentre, prospective, patient-reported pharmacovigilance monitoring system

ECCO'20 Vienna

Year: 2020
Authors:

P. THOMAS1, R. West2, M. Russel3, J. Jansen4, J. van Lint5, N. Jessurun5, T. Römkens6, F. Hoentjen1

1Radboud University Medical Centre, Gastroenterology, Nijmegen, The Netherlands, 2Franciscus Gasthuis and Vlietland, Gastroenterology, Rotterdam, The Netherlands, 3Medisch Spectrum Twente, Gastroenterology, Enschede, The Netherlands, 4Onze Lieve Vrouw Gasthuis, Gastroenterology, Amsterdam, The Netherlands, 5Pharmacovigilance Centre LAREB, Pharmacovigilancy, ‘s-Hertogenbosch, The Netherlands, 6Jeroen Bosch Ziekenhuis, Gastroenterology, ‘s-Hertogenbosch, The Netherlands

P331 Productivity loss in patients with inflammatory bowel disease receiving treatment for iron deficiency anaemia: A comparison of ferric maltol and IV ironECCO'20 Vienna
Year: 2020
Authors: S. Howaldt1, I. Jacob2, M. Sampson3, F. Akriche4

1MZV für Immunologie, Gastroenterology, Hamburg, Germany, 2Health Economics and Outcomes Research Ltd, Health Economics, Cardiff, UK, 3Shield Therapeutics PLC, Medical, London, UK, 4Norgine Ltd, Medical, Rueil Malmaison, France

Corrigendum:

In the originally published version of this poster presentation, the below corrections have been made.

Upon the original publication, the Results section indicated that the primary non-inferiority endpoint was met. This should have read: “The primary non-inferiority endpoint was not met."

P332 Mindfulness-based stress reduction and cognitive intervention improve the health-related quality-of-life and ability to work in Crohn’s disease patients: A randomised controlled trial

ECCO'20 Vienna

Year: 2020
Authors:

D. Schwartz1, R. Sergienko2, G. Goren3, S. Reggev3, M. Friger2, A. Nemirovsky4, A. Monsonego4, D. Greenberg5, O. Sarid3, V. Slonim-Nevo3, S. Odes6, Israeli IBD NUcleua IIRN

1Department of Gastroenterology, Soroka Medical Center, Beer Sheva, Israel, 2Department of Public Health, Ben-Gurion University of the Negev, Beer Sheva, Israel, 3Department of Social Work, Ben-Gurion University of the Negev, Beer Sheva, Israel, 4Department of Bacteriology and Immunology, Ben-Gurion University of the Negev, Beer Sheva, Israel, 5Department of Health Systems Management, Ben-Gurion University of the Negev, Beer Sheva, Israel, 6Department of Health Sciences, Ben-Gurion University of the Negev, Metar, Israel

P333 Biologic longevity: Withdrawal of drugs due to remission is rare in clinical practice

ECCO'20 Vienna

Year: 2020
Authors:

E. Sharma, G. Cunningham, P. Dawson, F. D’Errico, S. Honap, S. Lim, R. Luber, S. Meade, P. Pavlidis, R. Reynolds, P. Irving

Guy’s and St Thomas’ NHS Foundation Trust, St Thomas Hospital, London, UK

P334 Impact of disease duration on tofacitinib efficacy in patients with ulcerative colitis

ECCO'20 Vienna

Year: 2020
Authors:

S. Travis1, I. Dotan2, S. Danese3, M. Chiorean4, J. Yamamoto-Furusho5, D. Ponce de Leon6, C. Su7, J. Paulissen8, E. Maller7, I. Modesto9, J.F. Colombel10

1Translational Gastroenterology Unit, Nuffield Department of Experimental Medicine- University of Oxford, Oxford, UK, 2Division of Gastroenterology, Rabin Medical Center- Petah Tikva- Israel and Sackler Faculty of Medicine- Tel Aviv University, Tel Aviv, Israel, 3Humanitas University- IBD Center, Division of Gastroenterology- Rozzano, Milan, Italy, 4Virginia Mason Medical Center, Seattle, WA, USA, 5IBD Clinic- Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición, Mexico City, Mexico, 6Pfizer Inc., Lima, Peru, Peru, 7Pfizer Inc., Collegeville, PA, USA, 8Syneos Health, Morrisville, NC, USA, 9Pfizer Inc., New York, NY, USA, 10Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA

P335 Treatment strategies after mucosal healing (MH) in ulcerative colitis

ECCO'20 Vienna

Year: 2020
Authors:

A. Sitibondo1, A. Viola1, G. Costantino1, A. Centritto1, A. Belvedere1, V. Pisana1, A. Abbruzzese1, A. Alibrandi2, W. Fries1

1Inflammatory Bowel Disease Unit, Department of Clinical and Experimental Medicine, University of Messina, A.O.U. Policlinico ‘G. Martino’, Messina, Italy, 2Department of Economics, University of Messina, Messina, Italy

P336 Minimally invasive surgery is safe and feasible for luminal Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

M. Nnaji, Y.F. Chin, O. Pujji, B. Wilkinson, S. Mohan, N.A. Yassin

Royal Wolverhampton NHS Trust, Colorectal Surgery, Wolverhampton, UK

P337 Usefulness of drug-level monitoring in therapeutic guidance in patients with ulcerative colitis on anti-TNF-α maintenance therapy

ECCO'20 Vienna

Year: 2020
Authors:

E.H. Oh1, Y. A-Ran2, K. Ye-Jee3, K. Jeongseok1, N. Namseok1, P. Sang Hyoung4, Y. Dong-Hoon1, B. Jeong-Sik1, M. Seung-Jae1, Y. Suk-Kyun4, Y. Byong Duk4

1Asan Medical Center, University of Ulsan College of Medicine, Department of Gastroenterology, Seoul, Korea Republic of, 2Asan Medical Center, University of Ulsan College of Medicine, Inflammatory Bowel Disease Center, Seoul, Korea Republic of, 3Asan Medical Center, University of Ulsan College of Medicine, Department of Clinical Epidemiology and Biostatistics, Seoul, Korea Republic of, 4Asan Medical Center, University of Ulsan College of Medicine, Department of Gastroenterology and Inflammatory Bowel Disease Center, Seoul, Korea Republic of

P338 The effectiveness of a standardised biologic care pathway in the management and treatment of inflammatory bowel disease

ECCO'20 Vienna

Year: 2020
Authors:

N. Willett1, C.G. Heisler1, N. Nazer1, B. Currie1, K. Phalen-Kelly1, M. Stewart2, J. Jones2

1Nova Scotia Health Authority, Digestive Care and Endoscopy, Halifax, Canada, 2Dalhousie University, Medicine, Halifax, Canada

P339 Assessment of DNA-thioguanine nucleotide identifies patients at risk of thiopurine-induced leukopoenia in inflammatory bowel disease

ECCO'20 Vienna

Year: 2020
Authors:

X. Zhu1, K. Chao2, X. Gao2, M. Huang1, X.D. Wang1

1School of Pharmaceutical Sciences, Sun Yat-Sen Unversity, Guangzhou, China, 2Department of Gastroenterology, the Sixth Affiliated Hospital- Sun Yat-sen University, Guangzhou, China

P340 Comorbidity is associated with safety outcomes in vedolizumab- and ustekinumab-treated inflammatory bowel disease patientsECCO'20 Vienna
Year: 2020
Authors: V. Asscher1, V. Biemans2,3, M. Pierik3, G. Dijkstra4, A. Van der Meulen-de Jong1, M. Löwenberg5, S. van der Marel6, N. de Boer7, A. Bodelier8, J. Jansen9, R. West10, J. Haans3, W. van Dop2, R. Weersma4, F. Hoentjen2, J. Maljaars1, on behalf of the Dutch Initiative on Crohn and Colitis (ICC)

1Leiden University Medical Center, Department of Gastroenterology and Hepatology, Leiden, The Netherlands, 2Radboud University Medical Centre, Department of Gastroenterology and Hepatology, Nijmegen, The Netherlands, 3Maastricht University Medical Centre, Department of Gastroenterology and Hepatology, Maastricht, The Netherlands, 4University Medical Centre Groningen, Department of Gastroenterology and Hepatology, Groningen, The Netherlands, 5Amsterdam University Medical Centre- Academic Medical Centre, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands, 6Haaglanden Medical Centre, Department of Gastroenterology and Hepatology, Den Haag, The Netherlands, 7Amsterdam University Medical Centre- Vrije Universiteit Amsterdam, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands, 8Amphia Hospital, Department of Gastroenterology and Hepatology, Breda, The Netherlands, 9Onze Lieve Vrouwe Gasthuis, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands, 10Franciscus Gasthuis and Vlietland, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands

P341 Induction of response and remission: a network meta-analysis of induction studies comparing ontamalimab with other treatments for moderate-to-severe ulcerative colitis

ECCO'20 Vienna

Year: 2020
Authors:

A. Vickers1, A. Nag2, B. Devine3, B.E. Sands4, R. Panaccione5, L. Peyrin-Biroulet6, S. Danese7, S. Vermeire8, K.J. Gorelick9, M. Goetsch10, L. Hartley1

1Department of Data Analytics and Design Strategy, RTI Health Solutions, Manchester, UK, 2Outcomes Research and Epidemiology, Shire - a Takeda Company, Health Economics, Lexington, USA, 3School of Pharmacy, University of Washington, Seattle, USA, 4Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai Medical Center, New York, USA, 5Division of Gastroenterology, University of Calgary, Calgary, Canada, 6Department of Gastroenterology, University Hospital of Nancy-Brabois, Vandœuvre-lès-Nancy, France, 7IBD Center, Humanitas University, Milan, Italy, 8Department of Gastroenterology, University Hospital Leuven, Leuven, Belgium, 9Zymo Consulting Group, Clinical Development, Newtown Square, USA, Clinical Development, 10Shire - a Takeda compa#ny, Zug, Switzerland

P342 Diagnostic accuracy of rectal bleeding and stool frequency in predicting mucosal healing in patients with ulcerative colitis in the tofacitinib OCTAVE Phase 3 induction studies

ECCO'20 Vienna

Year: 2020
Authors:

J.F. Colombel1, A.G. Bushmakin2, J.C. Cappelleri2, N. Kulisek3, G.O. Santana4, N. Lawendy3, D. Ponce de Leon5, P.L. Lakatos6

1Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA, 2Pfizer Inc., Groton, CT, USA, 3Pfizer Inc., Collegeville, PA, USA, 4University of the State of Bahia, Salvador, Bahia, Brazil, 5Pfizer Inc., Lima, Peru, Peru, 6McGill University Health Center, Montreal, Québec, Canada